Information for consumers
ESBRIET (also known as pirfenidone) is a prescription medicine used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a condition in which the tissue in the lungs becomes scarred over time, making it difficult to breathe.
In some patients, ESBRIET has been associated with drug-induced liver injury (DILI), which can be serious and life-threatening.
Before taking ESBRIET, patients should talk to their healthcare professional if they have, or have had, liver problems. ESBRIET may cause liver problems and other abnormal blood test results. Patients with severe or end-stage liver disease should not use ESBRIET. ESBRIET should be used with caution and careful monitoring in patients with mild or moderate liver issues. Before and during treatment, patients should have blood tests done to check their liver function.
If patients experience signs of liver injury such as, tiredness, yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, or loss of appetite, they need to stop taking ESBRIET and seek immediate medical attention.
Patients should discuss any questions or concerns about this information with their healthcare professional.
Information for healthcare professionals
Healthcare professionals are advised to:
-
perform liver function tests (ALT, AST, and bilirubin) before initiating treatment with ESBRIET, subsequently at monthly intervals for the first 6 months, and then every 3 months thereafter.
-
promptly measure liver function tests in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.
-
not use ESBRIET in patients with severe hepatic impairment or end-stage liver disease.
-
use ESBRIET with caution in patients with pre existing mild to moderate hepatic impairment (Child-Pugh Class A and B).
Healthcare professionals are reminded to adjust or discontinue ESBRIET therapy in patients with confirmed elevations in ALT, AST or bilirubin as indicated in the table below:
LABORATORY VALUES/
SIGNS OR SYMPTOMS OF LIVER INJURY |
ACTION |
ALT and/or AST elevation to
>3 to <5 times ULN* without hyperbilirubinemia |
-
Confounding medicinal products should be discontinued, other causes excluded, and the patient monitored closely.
-
As clinically appropriate, ESBRIET can be continued at the recommended dose, reduced or temporarily discontinued.
-
Once ALT and AST levels have resolved, ESBRIET may be re-escalated to the recommended daily dose and continued, if tolerated and the patient should be monitored closely.
|
ALT and/or AST elevation to
>3 to <5 times ULN* with clinical signs or symptoms indicative of liver injury OR hyperbilirubinemia (excluding patients with known predominantly unconjugated hyperbilirubinemia, e.g., Gilbert’s syndrome) |
-
ESBRIET should be discontinued promptly.
-
The patient should be monitored closely until resolution of elevated ALT, AST, bilirubin, and symptoms.
-
The patient should NOT be re-challenged with ESBRIET.
|
|
ALT and/or AST elevation to ≥5 times ULN* regardless of the level of serum bilirubin |
-
ESBRIET should be discontinued promptly.
-
The patient should be monitored closely until resolution of elevated ALT, AST, and bilirubin.
-
The patient should not be re-challenged with ESBRIET.
|
*the upper limit of normal
Action taken by Health Canada
Health Canada, in collaboration with Hoffmann-La Roche Limited, has updated the Warnings and Precautions, Adverse Reactions (Post-Market Adverse Drug Reactions) and Dosage and Administration sections of the Canadian Product Monograph (CPM) for ESBRIET to include this new safety information.
Health Canada is communicating this important safety information to healthcare professionals and Canadians via the
Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system as well as through social media channels, including LinkedIn and Twitter.